Skip to main content

Table 1 Baseline characteristics of the included studies

From: Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis

First author (publication year)

Study design

No of patients

Group

Age (year)

Male (%)

Genotype (%)

SVR (%)

Fibrosis-4 index

HCV-RNA (log IU/mL)

Baseline LDL (mg/dL)

Exclusion criteria

Özdoğan (2020)

NA

93

SOF/LDV

64.1 (12.8)a

32.3

1: 96.7

2: 2.5

4: 0.8

SVR12: 98.4

NA

3.5 (10.0)a

81.7 (28.4)a

HIV or HBV infection, HCC, liver transplant, patients taking lipid-lowering agents

28

PTVr/OBV + DSV

64.1 (14.3)a

85.7

3.0 (7.5)a

89.7 (26.2)a

Inoue (2018)

NA

85

SOF/LDV

64.4 (13.3)a

43.5

1b: 100

SVR24: 97.8

3.4 (2.4)a

NA

102.8 (25.5)a

NA

46

SOF/RBV

62.0 (15.3)a

32.6

2: 100

SVR24: 98.8

3.5 (2.8)a

103.2 (28.0)a

85

ASV/DCV

68.3 (10.5)a

38.8

1b: 100

SVR24: 81.2

4.3 (2.9)a

98.3 (29.0)a

Endo (2017)

Retrospective cohort study

132

SOF/LDV

66.7 (13.1)a

37.1

1b: 100

SVR12: 100

4.7 (4.0)a

5.9 (0.87)a

89.2 (28.5)a

HIV infection, HCC, decompensated cirrhosis

121

ASV/DCV

68.4 (11.8)a

48.8

1b: 100

SVR12: 100

4.9 (3.3)a

5.9 (0.78)a

82.8 (27.2)a

Kan (2017)

NA

55

SOF/LDV

70.0 (20–86)c

56.4

1a/1b: 9/91

SVR12: 100

47.3% (≥ 3.25)

6.1 (2.5–7.2)c

77.0 (34–139)c

Decompensated cirrhosis, patients taking lipid-lowering agents

40

PTVr/OBV

67.0 (46–85)c

72.5

1b: 100

SVR12: 100

55.0% (≥ 3.25)

6.2 (3.9–7.3)c

75.5 (38–134)c

Notsumata (2017)

NA

140

SOF/LDV

71.0 (26–87)c

40.2

NA

SVR12: 99.1

NA

NA

90.2 (22.9)a

NA

100

SOF/RBV

SVR12: 98.7

98.1 (25.3)a

173

ASV/DCV

SVR12: 93.8

88.7 (30.0)a

50

PTVr/OBV

SVR12: 96.3

101.3 (24.4)a

Hashimoto (2016)

Retrospective cohort study

76

SOF/LDV

69.0 (63.0- 75.0)b

40.8

1: 100

NA

67.1% (≥ 3.25)

6.0 (5.6–6.4)b

87.5 (68.6–105.8) b

Patients taking lipid-lowering agents

24

ASV/DCV

76.0 (69.0- 80.0)b

33.3

1: 100

NA

79.2% (≥ 3.25)

6.1 (5.4–6.4)b

80.2 (65.3–94.6)b

  1. Data were presented as mean (standard deviation)a, median (interquartile range)b, or median (range)c
  2. LDL low-density lipoprotein; SVR sustained virologic response; SOF sofosbuvir; LDV ledipasvir; DCV daclatasvir; ASV asunaprevir; PTVr paritaprevir/ritonavir; OBV ombitasvir; RBV ribavirin; HIV human immunodeficiency virus; HCC hepatocellular carcinoma; NA not available